253 related articles for article (PubMed ID: 17665197)
1. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
2. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
3. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
5. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
Tanaka H; Ito T; Kyo T; Kimura A
Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
7. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins.
Shen J; Wu Y; Shi L; Liu J; Liu S; Guan Z; Yin Z
Appl Microbiol Biotechnol; 2007 Aug; 76(1):141-9. PubMed ID: 17562041
[TBL] [Abstract][Full Text] [Related]
10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
11. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
12. Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases.
Shin JN; Park SY; Cha JH; Park JY; Lee BR; Jung SA; Lee ST; Yun CW; Seol DW; Kim TH
Exp Cell Res; 2006 Nov; 312(19):3892-8. PubMed ID: 16996498
[TBL] [Abstract][Full Text] [Related]
13. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
14. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
16. [Adeno-associated virus mediated tumor necrosis factor related apoptosis inducing ligand gene transfected into hepatocellular carcinoma cells by ultrasound microbubble intensifier: an experimental study].
Xia JT; Xu B; Wang SC; Lai YY; Wu ZF; Li SH; Li W
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1846-50. PubMed ID: 19040022
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor effect of eukaryotic expressing plasmid containing soluble tumor necrotic factor-related apoptosis inducing ligand combined with human angiostatin Kringle (1 - 3) genes on human gastric cancer xenografts in nude mice].
Sun W; Jiang Z; Xiang TX; Tao XH; Huang AL; Wang PL
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):841-5. PubMed ID: 19595126
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.
Uckun FM; Myers DE; Qazi S; Ozer Z; Rose R; D'Cruz OJ; Ma H
J Clin Invest; 2015 Mar; 125(3):1006-18. PubMed ID: 25621496
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G; Rimondi E; Celeghini C; Milani D; Secchiero P
J Cell Physiol; 2010 Feb; 222(2):357-64. PubMed ID: 19877156
[TBL] [Abstract][Full Text] [Related]
20. TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia.
Jablonska E; Kiersnowska-Rogowska B; Aleksandrowicz-Bukin M; Rogowski F; Sawicka-Powierza J
Neoplasma; 2008; 55(1):51-4. PubMed ID: 18190241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
